modelClopidogrel
Extends from Pharmacolibrary.Drugs.ATC.B.B01AC04.
Information
| name: | Clopidogrel | |
| ATC code: | B01AC04 | route: | oral |
| compartments: | 1 | |
| dosage: | 75 | mg |
| volume of distribution: | 324 | L |
| clearance: | 259 | L/h |
| other parameters in model implementation | ||
Clopidogrel is an oral antiplatelet agent that inhibits ADP-induced platelet aggregation by antagonizing the P2Y12 receptor. It is used to prevent atherothrombotic events in patients with myocardial infarction, stroke, or established peripheral arterial disease. Clopidogrel is currently approved and widely used in clinical practice.
Pharmacokinetics
Pharmacokinetic parameters reported for healthy adult male and female volunteers receiving a single 75 mg oral dose of clopidogrel.
References
Mahar, KM, et al., & Goulooze, SC (2024). Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia. Clinical pharmacokinetics 63(9) 1327–1341. DOI:10.1007/s40262-024-01417-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39259485
Zhang, L, et al., & Yan, X (2022). Semi-mechanistic population pharmacokinetics analysis reveals distinct CYP2C19 dependency in the bioactivation of vicagrel and clopidogrel to active metabolite M15-2. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 177 106264–None. DOI:10.1016/j.ejps.2022.106264 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35868434
Rekić, D, et al., & Hamrén, B (2021). Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis- and Non-Dialysis-Dependent Patients with Chronic Kidney Disease. Clinical pharmacokinetics 60(6) 759–773. DOI:10.1007/s40262-020-00974-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/33486718
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)